Both BGLF1 and LF1 sequences were expressed in 80% of Her2+ tumors, and were upregulated approximately two-fold higher in the Her2+ breast cancer tumor subtypes as compared to the results for all other tumors (Figure 5, panels A and B, respectively); under these experimental conditions, no expression was observed in normal breast tissue controls. This evidence concerns the gene ERBB2 and breast carcinoma.